TBCRC 019: An open label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel (nab-PAC) with or without the anti-death receptor 5 (DR5) monoclonal antibody tigatuzumab (TIG) in patients with metastatic triple negative breast cancer (TNBC).
Year: 2013
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Christos Vaklavas, Vandana Gupta Abramson, Nancy U. Lin, Minetta C. Liu, Hope S. Rugo, Rita Nanda, Anna Maria Storniolo, Tiffany A. Traina, Yufeng Li, Sujata Patil, Daniel F. Hayes, Catherine H. Van Poznak, Julie R. Nangia, William Johnson Irvin, Helen Krontiras, Jennifer F. De Los Santos, Paul Haluska, Antonio C. Wolff, Andres Forero-Torres
Institutions: University of Alabama at Birmingham, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Dana-Farber Cancer Institute, Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, University of California, San Francisco, University of Chicago, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, U-M Rogel Cancer Center, Rush University Medical Center, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Mayo Clinic, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2247947798